老年营养风险指数预测仑伐替尼在肝细胞癌患者中的耐受性。
The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.
机构信息
Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo, Japan;
Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo, Japan.
出版信息
In Vivo. 2022 Mar-Apr;36(2):865-873. doi: 10.21873/invivo.12775.
Abstract
BACKGROUND/AIM: We aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC).
PATIENTS AND METHODS
We retrospectively evaluated 61 HCC patients treated with lenvatinib and compared those with low GNRI (≤98, n=26) to those with high GNRI (>98, n=35).
RESULTS
The discontinuation of lenvatinib due to adverse events was more frequent in the low GNRI group (46.2%) than in the high GNRI group (17.1%) (p=0.014). Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib. The progression-free survival in the low GNRI group was significantly shorter than that in the high GNRI group (p=0.047).
CONCLUSION
The GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.
摘要
背景/目的：我们旨在研究老年营养风险指数（GNRI）与肝癌（HCC）患者仑伐替尼耐受性之间的关系。
患者与方法
我们回顾性评估了 61 例接受仑伐替尼治疗的 HCC 患者，并将 GNRI 低（≤98，n=26）与 GNRI 高（>98，n=35）的患者进行比较。
结果
低 GNRI 组（46.2%）仑伐替尼因不良事件停药的频率高于高 GNRI 组（17.1%）（p=0.014）。多变量分析显示，低 GNRI（p=0.014）、甲状腺功能减退症（模型 1 p=0.021，模型 2 p=0.013）和高龄（p=0.026）与仑伐替尼停药独立相关。低 GNRI 组的无进展生存期明显短于高 GNRI 组（p=0.047）。
结论
GNRI 可能与 HCC 患者仑伐替尼的耐受性独立相关。
相似文献
1
The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.老年营养风险指数预测仑伐替尼在肝细胞癌患者中的耐受性。
In Vivo. 2022 Mar-Apr;36(2):865-873. doi: 10.21873/invivo.12775.
2
Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis.老年营养风险指数预测肝切除术后肝细胞癌的预后：倾向评分匹配分析。
Sci Rep. 2021 Apr 27;11(1):9038. doi: 10.1038/s41598-021-88254-z.
3
Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma.老年营养风险指数预测乙型肝炎病毒相关肝细胞癌老年患者肝切除术后的预后。
Sci Rep. 2018 Aug 22;8(1):12561. doi: 10.1038/s41598-018-30906-8.
4
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.营养指数作为不可切除肝细胞癌患者仑伐替尼治疗的预后指标。
Oncology. 2020;98(5):295-302. doi: 10.1159/000506293. Epub 2020 Feb 25.
5
Geriatric Nutritional Risk Index and the Survival of Patients with Hepatocellular Carcinoma: A Meta-Analysis.老年营养风险指数与肝细胞癌患者生存的关系：一项荟萃分析。
Horm Metab Res. 2023 Oct;55(10):692-700. doi: 10.1055/a-2091-2072. Epub 2023 Jun 29.
6
The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.循环 IgM 与老年营养风险指数联合预测接受免疫检查点抑制剂治疗的肝细胞癌患者的预后。
Int Immunopharmacol. 2023 Oct;123:110704. doi: 10.1016/j.intimp.2023.110704. Epub 2023 Jul 26.
7
Impact of Geriatric Nutritional Risk Index After Initial Hepatectomy for Hepatocellular Carcinoma: a Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).老年营养风险指数对肝细胞癌初始肝切除术后的影响：广岛临床肿瘤外科研究组（HiSCO）的回顾性队列研究。
J Gastrointest Surg. 2023 Jun;27(6):1152-1158. doi: 10.1007/s11605-023-05624-w. Epub 2023 Mar 3.
8
Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.仑伐替尼致不可切除肝细胞癌患者甲状腺功能异常。
Endocr J. 2019 Sep 28;66(9):787-792. doi: 10.1507/endocrj.EJ19-0140. Epub 2019 May 30.
9
Prognostic value of geriatric nutritional risk index and prognostic nutritional index in hepatocellular carcinoma.老年营养风险指数和预后营养指数在肝细胞癌中的预后价值。
Clin Nutr ESPEN. 2024 Feb;59:355-364. doi: 10.1016/j.clnesp.2023.12.148. Epub 2023 Dec 30.
10
Lower Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict Postoperative Prognosis in Patients with Hepatocellular Carcinoma.低老年营养风险指数和预后营养指数预测肝癌患者的术后预后。
Nutrients. 2024 Mar 25;16(7):940. doi: 10.3390/nu16070940.
引用本文的文献
1
Geriatric nutritional risk index as a predictor of prognosis in hepatocellular carcinoma: A systematic review and meta-analysis.老年营养风险指数作为肝细胞癌预后的预测指标：一项系统评价和荟萃分析。
Pak J Med Sci. 2025 Apr;41(4):1244-1252. doi: 10.12669/pjms.41.4.11962.
2
Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.营养指标对不可切除肝细胞癌患者乐伐替尼治疗持续率的影响
In Vivo. 2025 Mar-Apr;39(2):988-999. doi: 10.21873/invivo.13904.
3
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.老年营养风险指数和新开发的评分系统对接受乐伐替尼治疗的不可切除肝细胞癌患者的预后预测
Sci Rep. 2025 Jan 2;15(1):72. doi: 10.1038/s41598-024-78539-4.
4
Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study.与乐伐替尼相关的肺部不良事件评估：一项上市后监测研究
In Vivo. 2025 Jan-Feb;39(1):346-352. doi: 10.21873/invivo.13834.
5
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.乐伐替尼与免疫检查点抑制剂在肝细胞癌中的应用：作用机制、临床疗效及未来展望
J Hematol Oncol. 2024 Dec 21;17(1):130. doi: 10.1186/s13045-024-01647-1.
6
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).乐伐替尼在晚期肝细胞癌中的临床应用作用及其耐药机制（综述）
Am J Cancer Res. 2024 Sep 15;14(9):4113-4171. doi: 10.62347/UJVP4361. eCollection 2024.
7
A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients.低老年营养风险指数与肝硬化患者的低肌肉量和不良预后相关。
Medicina (Kaunas). 2023 Nov 29;59(12):2099. doi: 10.3390/medicina59122099.
8
Correlation between preoperative systemic immune inflammation index, nutritional risk index, and prognosis of radical resection of liver cancer.术前全身免疫炎症指数、营养风险指数与肝癌根治性切除预后的相关性
World J Gastrointest Surg. 2023 Nov 27;15(11):2445-2455. doi: 10.4240/wjgs.v15.i11.2445.
9
Low geriatric nutritional risk index predicts poor prognosis in patients with cirrhosis: a retrospective study.低老年营养风险指数预示肝硬化患者预后不良：一项回顾性研究。
Front Nutr. 2023 Sep 20;10:1269399. doi: 10.3389/fnut.2023.1269399. eCollection 2023.
10
Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors.免疫检查点抑制剂和酪氨酸激酶抑制剂治疗男性肝细胞癌患者的预后意义与腰大肌指数的关系。
Hum Vaccin Immunother. 2023 Aug;19(2):2258567. doi: 10.1080/21645515.2023.2258567. Epub 2023 Sep 20.
本文引用的文献
1
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.一项全国多中心研究中，接受乐伐替尼治疗的日本不可切除肝细胞癌患者的真实世界数据。
Cancers (Basel). 2021 May 26;13(11):2608. doi: 10.3390/cancers13112608.
2
Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis.老年营养风险指数预测肝切除术后肝细胞癌的预后：倾向评分匹配分析。
Sci Rep. 2021 Apr 27;11(1):9038. doi: 10.1038/s41598-021-88254-z.
3
Advances in immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗进展。
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13.
4
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.仑伐替尼单药治疗美国不可切除肝细胞癌患者的真实世界疗效。
Future Oncol. 2021 Jul;17(21):2759-2768. doi: 10.2217/fon-2021-0242. Epub 2021 Apr 9.
5
Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.老年不可切除肝细胞癌患者仑伐替尼治疗后的肝功能。
Anticancer Res. 2021 Apr;41(4):2025-2032. doi: 10.21873/anticanres.14970.
6
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy.老年营养风险指数在既往接受过治疗的晚期非小细胞肺癌患者中进行免疫治疗后的预后价值。
Thorac Cancer. 2021 May;12(9):1366-1372. doi: 10.1111/1759-7714.13909. Epub 2021 Mar 12.
7
Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes.低预处理老年营养风险指数与骨髓增生异常综合征患者阿扎胞苷不耐受的关系。
Ann Nutr Metab. 2020;76(6):405-412. doi: 10.1159/000513542. Epub 2021 Mar 4.
8
Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel.老年营养风险指数作为接受多西他赛治疗的转移性去势抵抗性前列腺癌患者的预后标志物
Front Pharmacol. 2021 Jan 25;11:601513. doi: 10.3389/fphar.2020.601513. eCollection 2020.
9
Geriatric nutritional risk index as a predictor of complications and long-term outcomes in patients with gastrointestinal malignancy: a systematic review and meta-analysis.老年营养风险指数作为胃肠道恶性肿瘤患者并发症和长期预后的预测指标：一项系统评价和荟萃分析
Cancer Cell Int. 2020 Oct 31;20(1):530. doi: 10.1186/s12935-020-01628-7.
10
Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.乐伐替尼治疗不可切除肝细胞癌患者时握力的影响
Cancers (Basel). 2020 Aug 3;12(8):2146. doi: 10.3390/cancers12082146.
Zotero 插件